Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis
Published in Seminars in Arthritis and Rheumatism, 2023
Evaluating if initially starting glucocorticoid (GC) bridging leads to a higher probability of long-term GC and biological (b)DMARD use in rheumatoid arthritis (RA)-patients.
Recommended citation: van Ouwerkerk L, Bergstra SA, Maarseveen TD, Huizinga TWJ, Knevel R, Allaart CF. (2024) Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis.” Semin Arthritis Rheum.
Recommended citation: van Ouwerkerk L, Bergstra SA, Maarseveen TD, Huizinga TWJ, Knevel R, Allaart CF. (2024) Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis." Semin Arthritis Rheum.
Download Paper